Jean E. Abraham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jean E. Abraham has a total of 277 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Caldas
Department of Clinical Biochemistry and Institute of Metabolic Science, School of Clinical Medicine, University of Cambridge, Cambridge, UK
24 shared publications - Elena Provenzano
Addenbrookes Hospital and NIHR Cambridge Biomedical Research Centre, Cambridge, UK
16 shared publications - Raquel Manzano Garcia
Department of Oncology, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom
15 shared publications - Karen McAdam
Cambridge University NHS Foundation Trust, Cambridge, United Kingdom
14 shared publications - Oscar M. Rueda
MRC-Biostatistics Unit, University of Cambridge, School of Clinical Medicine, Cambridge CB2 0SR, UK
14 shared publications - Abigail Shea
Department of Oncology, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom
13 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Legends from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
Supplementary Figures 1-20 and Supplementary Tables 1-10 Legends
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Legends from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
Supplementary Figures 1-20 and Supplementary Tables 1-10 Legends
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 6 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
In vivo treatment causes permanent changes to a tumor’s drug response profile. A, Experimental framework of in vivo and ex vivo drug response profiling. B, High-throughput drug screening data of dissociated PDTX cells. AUC plots display the response of each tumor to drugs tested ex vivo. Color indicates the in vivo treatment to which each tumor was previously exposed. C, Dose–response curves of models 1040 (top) and 1141 (bottom) to olaparib and BMN-673. Plots compare the untreated PDTX tumors (black) to those previously treated in vivo with CT (red). D, Experimental framework to test alternative sequencing strategies of CT and olaparib in vivo using model 1040. Untreated PDTX tumors and those previously treated with CT or olaparib were each passaged into three cohorts of mice. These mice were left untreated or subsequently exposed to CT or olaparib. E, Estimated mean tumor growth for each experimental group. Panels display previous treatment groups (first-line treatment), and lines within each panel display the cohort of second-line treatment. F, Estimated log-daily growth rate of PDTX tumors, as predicted by the linear mixed models. Column panels display previous treatment groups (first-line treatment), and lines within each panel display the cohort of second-line treatment. G, Predicted tumor (log) volume at treatment end of each cohort treated sequentially with no treatment, CT, or olaparib based on the linear mixed models. Panels display previous treatment groups (first-line treatment), and boxes within each panel display the cohort of second-line treatment.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
In vivo treatment causes permanent changes to a tumor’s drug response profile. A, Experimental framework of in vivo and ex vivo drug response profiling. B, High-throughput drug screening data of dissociated PDTX cells. AUC plots display the response of each tumor to drugs tested ex vivo. Color indicates the in vivo treatment to which each tumor was previously exposed. C, Dose–response curves of models 1040 (top) and 1141 (bottom) to olaparib and BMN-673. Plots compare the untreated PDTX tumors (black) to those previously treated in vivo with CT (red). D, Experimental framework to test alternative sequencing strategies of CT and olaparib in vivo using model 1040. Untreated PDTX tumors and those previously treated with CT or olaparib were each passaged into three cohorts of mice. These mice were left untreated or subsequently exposed to CT or olaparib. E, Estimated mean tumor growth for each experimental group. Panels display previous treatment groups (first-line treatment), and lines within each panel display the cohort of second-line treatment. F, Estimated log-daily growth rate of PDTX tumors, as predicted by the linear mixed models. Column panels display previous treatment groups (first-line treatment), and lines within each panel display the cohort of second-line treatment. G, Predicted tumor (log) volume at treatment end of each cohort treated sequentially with no treatment, CT, or olaparib based on the linear mixed models. Panels display previous treatment groups (first-line treatment), and boxes within each panel display the cohort of second-line treatment.
- Open Access
Consensus Through Diversity: A Comprehensive Benchmark of Multi-Omic Approaches for Precision Breast Oncology
Emerging multi-omic profiling has made it feasible to subtype disease using multiple molecular layers. However, inconsistent preprocessing, heterogeneous implementations, variable evaluation, and limited reproducibility often constrain method selection. Here, we systematically benchmark 22 publicly available unsupervised approaches for bulk data on the TCGA-BRCA cohort across five modalities (RNA-seq, miRNA, DNA methylation, copy numbers, single nucleotide polymorphisms) and validate findings in two independent datasets, enabling a multi-layered comparison of performance, heterogeneous data support and interpretability. Most approaches fuse multi-omic data to produce a two-cluster solution largely aligned with ER status, with higher-resolution approaches further refining these into four coherent subclasses (angiogenic luminal, oxidative-phosphorylation/HER2-low luminal, immune-inflamed basal-like, and hyper-proliferative basal-like). Our benchmarking results indicate that methods based on similarity networks can efficiently produce stable, reliable partitions. Matrix factorisation and Bayesian factorisation algorithms produce rich latent representations, allowing quantification of feature and modality contributions, albeit at higher computational cost. Consensus clustering can be used on a case-by-case basis and refine partitions into more robust and generalisable findings. We aggregate our insights into a decision workflow that aligns with study goals, data characteristics, and computational resources, enabling optimal analytic strategies. This comprehensive assessment provides a practical roadmap for investigators seeking to extract reproducible, biologically meaningful subtypes from complex multi-omic datasets. We higlight the different technical and practical benefits and trade-offs that shape the selection and development of multi-omic approaches applied in precision oncology.
Open AccessConsensus Through Diversity: A Comprehensive Benchmark of Multi-Omic Approaches for Precision Breast Oncology
Emerging multi-omic profiling has made it feasible to subtype disease using multiple molecular layers. However, inconsistent preprocessing, heterogeneous implementations, variable evaluation, and limited reproducibility often constrain method selection. Here, we systematically benchmark 22 publicly available unsupervised approaches for bulk data on the TCGA-BRCA cohort across five modalities (RNA-seq, miRNA, DNA methylation, copy numbers, single nucleotide polymorphisms) and validate findings in two independent datasets, enabling a multi-layered comparison of performance, heterogeneous data support and interpretability. Most approaches fuse multi-omic data to produce a two-cluster solution largely aligned with ER status, with higher-resolution approaches further refining these into four coherent subclasses (angiogenic luminal, oxidative-phosphorylation/HER2-low luminal, immune-inflamed basal-like, and hyper-proliferative basal-like). Our benchmarking results indicate that methods based on similarity networks can efficiently produce stable, reliable partitions. Matrix factorisation and Bayesian factorisation algorithms produce rich latent representations, allowing quantification of feature and modality contributions, albeit at higher computational cost. Consensus clustering can be used on a case-by-case basis and refine partitions into more robust and generalisable findings. We aggregate our insights into a decision workflow that aligns with study goals, data characteristics, and computational resources, enabling optimal analytic strategies. This comprehensive assessment provides a practical roadmap for investigators seeking to extract reproducible, biologically meaningful subtypes from complex multi-omic datasets. We higlight the different technical and practical benefits and trade-offs that shape the selection and development of multi-omic approaches applied in precision oncology.
- Open Access
- 14 January 2026
- Published by Springer Nature in Cardio-Oncology
- Vol. 12 (1)
Abemaciclib-induced myocarditis in early breast cancer: a case report
Background: Abemaciclib, a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, is standard adjuvant therapy for hormone receptor (HR)-positive, HER2-negative early breast cancer. While gastrointestinal and haematologic toxicities are well recognised, cardiotoxicity—particularly myocarditis—is extremely rare. To our knowledge, myocarditis has not previously been reported in early breast cancer. This case describes a case of acute abemaciclib-induced myocarditis and explores a potential genetic predisposition involving an RHBDF2 germline variant affecting growth factor signalling pathways. Case presentation: A 39-year-old female with high-risk HR-positive, HER2-negative early breast cancer commenced adjuvant abemaciclib with letrozole following completion of chemotherapy and radiotherapy. Within 24 h, she developed acute chest pain with an elevated troponin I (8457 ng/L), new T-wave inversion on her ECG, and a reduced left ventricular ejection fraction (47%) on echocardiography. CT imaging excluded coronary or aortic pathology. Cardiac magnetic resonance imaging demonstrated mid-inferoseptal late gadolinium enhancement consistent with acute myocarditis. Abemaciclib was immediately discontinued, and bisoprolol and ramipril were initiated. Her symptoms and cardiac function improved rapidly, with normalisation of left ventricular ejection fraction (68%). Genetic testing identified a germline RHBDF2 missense variant, which is predicted to alter tumour necrosis factor alpha and epidermal growth factor signalling, potentially predisposing to cardiomyocyte injury based on published in vitro evidence. Conclusions: To our knowledge, this is among the earliest reported cases of abemaciclib-induced myocarditis in early breast cancer. Awareness of this potential toxicity is crucial, as early recognition and management is pivotal to prevent lasting cardiac dysfunction. Genetic variants influencing inflammatory or growth factor pathways may contribute to individual susceptibility, warranting further investigation. This case highlights the importance of combined cardio-oncology care in the early recognition of cardiotoxicity when introducing CDK4/6 inhibitors.
- 14 January 2026
- Published by Springer Nature in Cardio-Oncology
- Vol. 12 (1)
Open AccessAbemaciclib-induced myocarditis in early breast cancer: a case report
Background: Abemaciclib, a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, is standard adjuvant therapy for hormone receptor (HR)-positive, HER2-negative early breast cancer. While gastrointestinal and haematologic toxicities are well recognised, cardiotoxicity—particularly myocarditis—is extremely rare. To our knowledge, myocarditis has not previously been reported in early breast cancer. This case describes a case of acute abemaciclib-induced myocarditis and explores a potential genetic predisposition involving an RHBDF2 germline variant affecting growth factor signalling pathways. Case presentation: A 39-year-old female with high-risk HR-positive, HER2-negative early breast cancer commenced adjuvant abemaciclib with letrozole following completion of chemotherapy and radiotherapy. Within 24 h, she developed acute chest pain with an elevated troponin I (8457 ng/L), new T-wave inversion on her ECG, and a reduced left ventricular ejection fraction (47%) on echocardiography. CT imaging excluded coronary or aortic pathology. Cardiac magnetic resonance imaging demonstrated mid-inferoseptal late gadolinium enhancement consistent with acute myocarditis. Abemaciclib was immediately discontinued, and bisoprolol and ramipril were initiated. Her symptoms and cardiac function improved rapidly, with normalisation of left ventricular ejection fraction (68%). Genetic testing identified a germline RHBDF2 missense variant, which is predicted to alter tumour necrosis factor alpha and epidermal growth factor signalling, potentially predisposing to cardiomyocyte injury based on published in vitro evidence. Conclusions: To our knowledge, this is among the earliest reported cases of abemaciclib-induced myocarditis in early breast cancer. Awareness of this potential toxicity is crucial, as early recognition and management is pivotal to prevent lasting cardiac dysfunction. Genetic variants influencing inflammatory or growth factor pathways may contribute to individual susceptibility, warranting further investigation. This case highlights the importance of combined cardio-oncology care in the early recognition of cardiotoxicity when introducing CDK4/6 inhibitors.
- Open Access
- 5 January 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (1) , 194-206
Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial
The use of progestogens in breast cancer has been controversial. Recent preclinical studies have shown that ligand-bound progesterone receptor interacts directly with the estrogen receptor (ER) and reprograms ER transcriptional activity. Progestogen cotreatment enhances the antitumor activity of antiestrogen therapy in mouse xenografts. We report PIONEER, a 198-participant, three-arm, randomized phase 2b window-of-opportunity study for women with early-stage ER + breast cancer, which evaluated letrozole with or without megestrol at 40 mg or 160 mg daily. The primary endpoint was the change in tumor proliferation measured by Ki67 immunohistochemistry. Secondary and exploratory endpoints included a comparison of low versus higher dose of megestrol, safety, tolerability and biomarker subgroup analyses. The trial met its primary endpoint, with a greater reduction in proliferation seen when megestrol was added to letrozole. This effect was accompanied by reduced ER genomic binding at canonical binding sites in paired tumor biopsies, indicating reduced ER transcriptional activity. These results support further evaluation of low-dose megestrol, which has two mechanisms for potentially improving breast cancer outcomes in combination with standard antiestrogen therapy: alleviating hot flashes and thereby helping with treatment adherence, as well as a direct antiproliferative effect ( NCT03306472 ).
- 5 January 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (1) , 194-206
Open AccessEvaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial
The use of progestogens in breast cancer has been controversial. Recent preclinical studies have shown that ligand-bound progesterone receptor interacts directly with the estrogen receptor (ER) and reprograms ER transcriptional activity. Progestogen cotreatment enhances the antitumor activity of antiestrogen therapy in mouse xenografts. We report PIONEER, a 198-participant, three-arm, randomized phase 2b window-of-opportunity study for women with early-stage ER + breast cancer, which evaluated letrozole with or without megestrol at 40 mg or 160 mg daily. The primary endpoint was the change in tumor proliferation measured by Ki67 immunohistochemistry. Secondary and exploratory endpoints included a comparison of low versus higher dose of megestrol, safety, tolerability and biomarker subgroup analyses. The trial met its primary endpoint, with a greater reduction in proliferation seen when megestrol was added to letrozole. This effect was accompanied by reduced ER genomic binding at canonical binding sites in paired tumor biopsies, indicating reduced ER transcriptional activity. These results support further evaluation of low-dose megestrol, which has two mechanisms for potentially improving breast cancer outcomes in combination with standard antiestrogen therapy: alleviating hot flashes and thereby helping with treatment adherence, as well as a direct antiproliferative effect ( NCT03306472 ).
- Open Access
- 13 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial
Poly (ADP-ribose) polymerase inhibitors (PARPi) exploit DNA repair deficiency in germline BRCA1 and BRCA2 pathogenic variant (gBRCAm) cancers. Haematological toxicity limits chemotherapy-PARPi treatment combinations. In preclinical models we identified a schedule combining olaparib and carboplatin that avoids enhanced toxicity but maintains anti-tumour activity. We investigated this schedule in a neoadjuvant, phase II-III, randomised controlled trial for gBRCAm breast cancers (ClinicalTrials.gov ID:NCT03150576; PARTNER). The research arm included carboplatin (Area Under the Curve 5, 3-weekly); paclitaxel (80 mg/m2, weekly) day 1, plus olaparib (150 mg twice daily) day 3-14 (4 cycles), followed by anthracycline-containing chemotherapy (3 cycles); control arm gave chemotherapy alone. The primary endpoint, pathological complete response rate, showed no statistical difference between research 64.1% (25/39); control 69.8% (30/43) (p = 0.59). However, estimated survival outcomes at 36-months demonstrated improved event-free survival: research 96.4%, control 80.1% (p = 0.04); overall survival: research 100%, control 88.2% (p = 0.04) and breast cancer specific survival: research 100%, control 88.2% (p = 0.04). There were no statistical differences in relapse-free survival and distant disease-free survival, both were: research 96.4%, control 87.9% (p = 0.20). Similarly, local recurrence-free survival and time to second cancer were both: research 96.4%, control 87.8% (p = 0.20). The PARTNER trial identified a safe, tolerable schedule combining neoadjuvant chemotherapy with olaparib. This combination demonstrated schedule-dependent overall survival benefit in early-stage gBRCAm breast cancer. This result needs confirmation in larger trials.
- 13 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Open AccessNeoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial
Poly (ADP-ribose) polymerase inhibitors (PARPi) exploit DNA repair deficiency in germline BRCA1 and BRCA2 pathogenic variant (gBRCAm) cancers. Haematological toxicity limits chemotherapy-PARPi treatment combinations. In preclinical models we identified a schedule combining olaparib and carboplatin that avoids enhanced toxicity but maintains anti-tumour activity. We investigated this schedule in a neoadjuvant, phase II-III, randomised controlled trial for gBRCAm breast cancers (ClinicalTrials.gov ID:NCT03150576; PARTNER). The research arm included carboplatin (Area Under the Curve 5, 3-weekly); paclitaxel (80 mg/m2, weekly) day 1, plus olaparib (150 mg twice daily) day 3-14 (4 cycles), followed by anthracycline-containing chemotherapy (3 cycles); control arm gave chemotherapy alone. The primary endpoint, pathological complete response rate, showed no statistical difference between research 64.1% (25/39); control 69.8% (30/43) (p = 0.59). However, estimated survival outcomes at 36-months demonstrated improved event-free survival: research 96.4%, control 80.1% (p = 0.04); overall survival: research 100%, control 88.2% (p = 0.04) and breast cancer specific survival: research 100%, control 88.2% (p = 0.04). There were no statistical differences in relapse-free survival and distant disease-free survival, both were: research 96.4%, control 87.9% (p = 0.20). Similarly, local recurrence-free survival and time to second cancer were both: research 96.4%, control 87.8% (p = 0.20). The PARTNER trial identified a safe, tolerable schedule combining neoadjuvant chemotherapy with olaparib. This combination demonstrated schedule-dependent overall survival benefit in early-stage gBRCAm breast cancer. This result needs confirmation in larger trials.
- Open Access
- 1 April 2025
- Published by Elsevier in European Journal of Radiology
- Vol. 187, 112086
Image normalization techniques and their effect on the robustness and predictive power of breast MRI radiomics
- 1 April 2025
- Published by Elsevier in European Journal of Radiology
- Vol. 187, 112086
Open AccessImage normalization techniques and their effect on the robustness and predictive power of breast MRI radiomics
- Open Access
- 1 February 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
A coclinical trial framework reveals concordant patient–PDTX drug responses. A, Experimental framework (consisting of two trial designs) and associated analytical approach, with modeling metrics used to assess drug response. B and C, TV growth curves displaying linear mixed model fits of trial designs 1 (B) and 2 (C) over treatment duration. Treatment arm for each PDTX model corresponds to the clinical treatment of the matched patient. D and E, Analytical metrics derived from mathematical modeling (as in A). Change in growth rate (top) and estimated difference in the AUC (bottom) for trial design 1 (D) and growth rate under treatment (top) and predicted volume at treatment end (bottom) for trial design 2 (E). F, Box plots displaying growth rate under treatment (top) and predicted volume at treatment end (bottom) for trial design 2 between pCR and non-pCR models. Statistical significance is calculated using the Wilcoxon test.
- 1 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
A coclinical trial framework reveals concordant patient–PDTX drug responses. A, Experimental framework (consisting of two trial designs) and associated analytical approach, with modeling metrics used to assess drug response. B and C, TV growth curves displaying linear mixed model fits of trial designs 1 (B) and 2 (C) over treatment duration. Treatment arm for each PDTX model corresponds to the clinical treatment of the matched patient. D and E, Analytical metrics derived from mathematical modeling (as in A). Change in growth rate (top) and estimated difference in the AUC (bottom) for trial design 1 (D) and growth rate under treatment (top) and predicted volume at treatment end (bottom) for trial design 2 (E). F, Box plots displaying growth rate under treatment (top) and predicted volume at treatment end (bottom) for trial design 2 between pCR and non-pCR models. Statistical significance is calculated using the Wilcoxon test.